|
1）Estcourt LJ, Stanworth SJ, Murphy MF. Platelet transfusions for patients with haematological malignancies: who needs them? Br J Haematol. 2011; 154: 425-40
|
|
|
|
2）Wandt H, Schaefer-Eckart K, Wendelin K, et al. Therapeutic platelet transfusion versus routine prophylactic transfusion in patients with haematological malignancies: an open-label, multicentre, randomised study. Lancet. 2012; 380: 1309-16
|
|
|
|
|
|
3）Stanworth SJ, Estcourt LJ, Powter G, et al. A no-prophylaxis platelet-transfusion strategy for hematologic cancers. N Engl J Med. 2013; 368: 1771-80
|
|
|
|
|
|
4）Kumar A, Mhaskar R, Grossman BJ, et al. Platelet transfusion: a systematic review of the clinical evidence. Transfusion. 2015; 55: 1116-27
|
|
|
|
|
|
5）Stanworth SJ, Estcourt LJ, Llewelyn CA, et al. Impact of prophylactic platelet transfusions on bleeding events in patients with hematologic malignancies: a subgroup analysis of a randomized trial. Transfusion. 2014; 54: 2385-93
|
|
|
|
|
|
6）Rebulla P, Finazzi G, Marangoni F, et al. The threshold for prophylactic platelet transfusions in adults with acute myeloid leukemia. N Engl J Med. 1997; 337: 1870-5
|
|
|
|
|
|
7）Zumberg MS, del Rosario ML, Nejame CF, et al. A prospective randomized trial of prophylactic platelet transfusion and bleeding incidence in hematopoietic stem cell transplant recipients: 10,000/L versus 20, 000/microL trigger. Biol Blood Marrow Transplant. 2002; 8: 569-76
|
|
|
|
|
|
8）Estcourt L, Stanworth S, Doree C, et al. Prophylactic platelet transfusion for prevention of bleeding in patients with haematological disorders after chemotherapy and stem cell transplantation. Cochrane Database Syst Rev. 2012; 5: CD004269
|
|
|
|
|
|
9）Zeidler K, Arn K, Senn O, et al. Optimal preprocedural platelet transfusion threshold for central venous catheter insertions in patients with thrombocytopenia. Transfusion. 2011; 51: 2269-76
|
|
|
|
|
|
10）Haas B, Chittams JL, Trerotola SO. Large-bore tunneled central venous catheter insertion in patients with coagulopathy. J Vasc Interv Radiol. 2010; 21: 212-7
|
|
|
|
|
|
11）Kaufman RM, Djulbegovic B, Gernsheimer T, et al. Platelet transfusion: a clinical practice guideline from the AABB. Ann Intern Med. 2015; 162: 205-13
|
|
|
|
|
|
12）Hopkins CK, Goldfinger D. Platelet transfusions in heparin-induced thrombocytopenia: a report of four cases and review of the literature. Transfusion. 2008; 48: 2128-32
|
|
|
|
|
|
13）Zhou A, Mehta RS, Smith RE. Outcomes of platelet transfusion in patients with thrombotic thrombocytopenic purpura: a retrospective case series study. Ann Hematol. 2015; 94: 467-72
|
|
|
|
|
|
14）Swisher KK, Terrell DR, Vesely SK, et al. Clinical outcomes after platelet transfusions in patients with thrombotic thrombocytopenic purpura. Transfusion. 2009; 49: 873-87
|
|
|
|
|
|
15）Goel R, Ness PM, Takemoto CM, et al. Platelet transfusions in platelet consumptive disorders are associated with arterial thrombosis and in-hospital mortality. Blood. 2015; 125: 1470-6
|
|
|
|
|
|
16）Nachman RL, Rafii S. Platelets, petechiae, and preservation of the vascular wall. N Engl J Med. 2008; 359: 1261-70
|
|
|
|
|
|
17）Hanson SR, Slichter SJ. Platelet kinetics in patients with bone marrow hypoplasia: evidence for a fixed platelet requirement. Blood. 1985; 66: 1105-9
|
|
|
|
|
|
18）Morowski M, Vogtle T, Kraft P, et al. Only severe thrombocytopenia results in bleeding and defective thrombus formation in mice. Blood. 2013; 121: 4938-47
|
|
|
|
|
|
19）Slichter SJ, Harker LA. Thrombocytopenia: mechanisms and management of defects in platelet production. Clin Haematol. 1978; 7: 523-39
|
|
|
|
|
|
20）Slichter SJ, Kaufman RM, Assmann SF, et al. Dose of prophylactic platelet transfusions and prevention of hemorrhage. N Engl J Med. 2010; 362: 600-13
|
|
|
|
|
|
21）Segal HC, Briggs C, Kunka S, et al. Accuracy of platelet counting haematology analysers in severe thrombocytopenia and potential impact on platelet transfusion. Br J Haematol. 2005; 128: 520-5
|
|
|
|
|
|
22）Goerge T, Ho-Tin-Noe B, Carbo C, et al. Inflammation induces hemorrhage in thrombocytopenia. Blood. 2008; 111: 4958-64
|
|
|
|
|
|
23）Ho-Tin-Noe B, Goerge T, Cifuni SM, et al. Platelet granule secretion continuously prevents intratumor hemorrhage. Cancer Res. 2008; 68: 6851-8
|
|
|
|
|
|
24）Morrell CN, Aggrey AA, Chapman LM, et al. Emerging roles for platelets as immune and inflammatory cells. Blood. 2014; 123: 2759-67
|
|
|
|
|
|
25）de Stoppelaar SF, vanʼt Veer C, van der Poll T. The role of platelets in sepsis. Thromb Haemost. 2014; 112: 666-77
|
|
|
|
|
|
26）Clark SR, Ma AC, Tavener SA, et al. Platelet TLR4 activates neutrophil extracellular traps to ensnare bacteria in septic blood. Nat Med. 2007; 13: 463-9
|
|
|
|
|
|
27）Xiang B, Zhang G, Guo L, et al. Platelets protect from septic shock by inhibiting macrophage-dependent inflammation via the cyclooxygenase 1 signalling pathway. Nat Commun. 2013; 4: 2657
|
|
|
|
|
|
28）Gudbrandsdottir S, Hasselbalch HC, Nielsen CH. Activated platelets enhance IL-10 secretion and reduce TNF-alpha secretion by monocytes. J Immunol. 2013; 191: 4059-67
|
|
|
|
|
|
29）de Stoppelaar SF, vanʼt Veer C, Claushuis TA, et al. Thrombocytopenia impairs host defense in gram-negative pneumonia-derived sepsis in mice. Blood. 2014; 124: 3781-90
|
|
|
|
|
|
30）de Stoppelaar SF, Vanʼt Veer C, Roelofs JJ, et al. Platelet and endothelial cell P-selectin are required for host defense against Klebsiella pneumoniae-induced pneumosepsis. J Thromb Haemost. 2015; 13: 1128-38
|
|
|
|
|
|
31）Nevo S, Fuller AK, Zahurak ML, et al. Profound thrombocytopenia and survival of hematopoietic stem cell transplant patients without clinically significant bleeding, using prophylactic platelet transfusion triggers of 10 x 10(9) or 20 x 10(9) per L. Transfusion. 2007; 47: 1700-9
|
|
|
|
|